BDTX
Black Diamond Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.12
+0.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 70.0M | — | — | — |
| Cost of Revenue | 27.0K | 325.0K | — | 437.0K | — |
| Gross Profit | (27.0K) | 69.7M | — | (437.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 28.1M | 33.6M | 51.3M | 58.9M | 64.4M |
| SG&A Expense | 16.4M | 16.6M | 27.5M | 27.1M | 28.4M |
| General & Admin Expense | 16.4M | 16.6M | 27.5M | 27.1M | 28.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 7.3M | (325.0K) | — | — | — |
| Total Operating Expenses | 51.9M | 49.8M | 78.8M | 86.0M | 92.8M |
| Cost and Expenses | 51.9M | 50.1M | 78.8M | 86.5M | 92.8M |
| Operating Income (EBIT) | (51.9M) | 19.9M | (78.8M) | (86.5M) | (92.8M) |
| Non-Operating | |||||
| Interest Income | 4.3M | 4.1M | 2.2M | 1.9M | 2.0M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.3M | 4.1M | 2.2M | 1.9M | 2.0M |
| Other Non-Op Income/Expense | 9.3M | 2.5M | 9.1M | 4.0M | 1.7M |
| Non-Operating Income (excl Interest) | (10.8M) | (2.5M) | (9.1M) | (4.0M) | (1.7M) |
| EBT (Pre-Tax Income) | (42.6M) | 22.4M | (69.7M) | (82.4M) | (91.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (42.6M) | 22.4M | (69.7M) | (82.4M) | (91.2M) |
| Earnings from Cont. Ops | (42.6M) | 22.4M | (69.7M) | (82.4M) | (91.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (42.6M) | 22.4M | (69.7M) | (82.4M) | (91.2M) |
| Per Share | |||||
| Basic EPS | ($0.74) | $0.39 | ($1.27) | ($1.88) | ($2.52) |
| Diluted EPS | ($0.74) | $0.39 | ($1.27) | ($1.88) | ($2.52) |
| Revenue Per Share | $0.00 | $1.23 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 57.4M | 56.9M | 55.0M | 44.0M | 36.2M |
| Diluted Shares Outstanding | 57.4M | 57.6M | 55.0M | 44.0M | 36.2M |
| Profitability Metrics | |||||
| EBITDA | (40.9M) | 22.7M | (69.3M) | (82.0M) | (90.7M) |
| D&A | 207.0K | 325.0K | 343.0K | 437.0K | 508.0K |
| EBIT | (41.1M) | 22.4M | (69.7M) | (82.4M) | (91.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026